Physician profile
David A Ziring
NPI 1164522033
$206,090.67
in general payments reported to CMS, 2019-2025
13 companies · $49K in 2025
The $49K reported for 2025 was more than what 98% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $15K · 2021: $20K · 2022: $4,237 · 2023: $27K · 2024: $63K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Honoraria: $12K · Travel and Lodging: $6,278 · Food and Beverage: $3,881 · Consulting Fee: $2,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,644.00 |
| Honoraria | $11,840.00 |
| Travel and Lodging | $6,277.97 |
| Food and Beverage | $3,881.29 |
| Consulting Fee | $2,590.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $131,755.33 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $33,148.84 | 2023-2025 | Dupixent |
| Genzyme Corporation | $25,394.02 | 2024 | |
| Celltrion USA INC. | $14,742.06 | 2025 | Zymfentra, Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $668.16 | 2021-2023 | Zeposia |
| Regeneron Pharmaceuticals, INC. | $170.09 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $106.71 | 2019-2022 | |
| Lilly USA, LLC | $39.85 | 2023 | |
| Dexcom, INC. | $27.09 | 2024 | Dexcom G6 Transmitter |
| Janssen Scientific Affairs, LLC | $24.75 | 2019 | |
| Celgene Corporation | $13.77 | 2023 | Zeposia |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ziring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.